Activity of novel non-amphipathic cationic antimicrobial peptides against Candida species

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 5, 2006, Pages 899-907

  Burrows, Lori L ^a,b   Stark, Margareta ^a   Chan, Celine ^a   Glukhov, Evgenia ^a   Sinnadurai, Selva ^a   Deber, Charles M ^a,b  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biofilms; CAPs; Fungi; Kaxins

Indexed keywords

ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; FLUCONAZOLE; LYSYLALANYLPHENYLALANYLLYSYLLYSYLTRYPTOPHYLALANYLLYSYLPHENYLALANYLALANYLALANYLLYSYLALANYLALANYLLYSYLALANYLALANYLALANYLAMIDE; LYSYLLYSYLLYSYLLYSYLLYSYLLYSYLALANYLALANYLPHENYLALANYLALANYLALANYLTRYPTOPHYLALANYLALANYLPHENYLALANYLALANYLALANYLAMIDE; LYSYLLYSYLLYSYLLYSYLLYSYLLYSYLALANYLALANYLTRYPTOPHYLALANYLALANYLTRYPTOPHYLALANYLALANYLTRYPTOPHYLALANYLALANYLAMIDE; LYSYLLYSYLLYSYLLYSYLLYSYLLYSYLALANYLNORVALYLTRYPTOPHYLALANYLNORVALYLTRYPTOPHYLNORVALYLALANYLTRYPTOPHYLNORVALYLALANYLAMIDE; LYSYLLYSYLLYSYLLYSYLLYSYLLYSYLALANYLTRYPTOPHYLALANYLALANYLTRYPTOPHYLALANYLALANYLTRYPTOPHYLALANYLAMIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; BIOFILM; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA TROPICALIS; CELL KILLING; CONTROLLED STUDY; FUNGAL STRAIN; HEMOLYSIS; MAMMAL CELL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OPPORTUNISTIC INFECTION; PEPTIDE SYNTHESIS; SEQUENCE ANALYSIS; SPECIES DIFFERENCE; STRAIN DIFFERENCE;

ANTIFUNGAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BIOFILMS; CANDIDA; ERYTHROCYTES; HUMANS; MICROBIAL SENSITIVITY TESTS; SPECIES SPECIFICITY; TIME FACTORS;

EID: 33645804783     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl056     Document Type: Article

References (26)

1. Pittet D, Li N, Woolson RF et al. Microbiological factors influencing the outcome of nosocomial bloodstream infections: A 6-year validated, population-based model. Clin Infect Dis 1997; 24: 1068-78.
2. Wright WL, Wenzel RP. Nosocomial Candida. Epidemiology, transmission, and prevention. Infect Dis Clin North Am 1997; 11: 411-25.
3. Fisher-Hoch SP, Hutwagner L. Opportunistic candidiasis: An epidemic of the 1980s. Clin Infect Dis 1995; 21: 897-904.
4. McNeil MM, Nash SL, Hajjeh RA et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001; 33: 641-7.
5. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994; 330: 263-72.
6. Wong-Beringer A, Kriengkauykiat J. Systemic antifungal therapy: New options, new challenges. Pharmacotherapy 2003; 23: 1441-62.
7. Vanden Bossche H, Dromer F, Improvisi I et al. Antifungal drug resistance in pathogenic fungi. Med Mycol 1998; 36 Suppl 1: 119-28.
8. Rogers TR. Antifungal drug resistance: Does it matter? Int J Infect Dis 2002; 6 Suppl 1: S47-53.
9. Marr KA. Invasive Candida infections: The changing epidemiology. Oncology (Huntingt) 2004; 18: 9-14.
10. Kullberg BJ, Oude Lashof AM. Epidemiology of opportunistic invasive mycoses. Eur J Med Res 2002; 7: 183-91.
11. Douglas W. Candida biofilms and their role in infection. Trends Microbiol 2003; 11: 30-36.
12. Kojic EM, Darouiche RO. Candida infections of medical devices. Clin Microbiol Rev 2004; 17: 255-67.
13. Stark M, Liu LP, Deber CM. Cationic hydrophobic peptides with antimicrobial activity. Antimicrob Agents Chemother 2002; 46: 3585-90.
14. Liu LP, Deber CM. Guidelines for membrane protein engineering derived from de novo designed model peptides. Biopolymers 1998; 47: 41-62.
15. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts - Second Edition: Approved Standard M27-A2. NCCLS, Villanova, PA, USA, 2002.
16. Brooun A, Liu S, Lewis K. A dose-response study of antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2000; 44: 640-6.
17. Finelli A, Burrows LL, DiCosmo FA et al. Colonization-resistant antimicrobial-coated peritoneal dialysis catheters: Evaluation in a newly developed rat model of persistent Pseudomonas aeruginosa peritonitis. Perit Dial Int 2002; 22: 27-31.
18. De Lucca AJ, Walsh TJ. Antifungal peptides: Novel therapeutic compounds against emerging pathogens. Antimicrob Agents Chemother 1999; 43: 1-11.
19. Muller FM, Lyman CA, Walsh TJ. Antimicrobial peptides as potential new antifungals. Mycoses 1999; 42 Suppl 2: 77-82.
20. Helmerhorst EJ, Venuleo C, Beri A et al. Candida glabrata is unusual with respect to its resistance to cationic antifungal proteins. Yeast 2005; 22: 705-14.
21. Hawser SP, Douglas LJ. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 1995; 39: 2128-31.
22. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: Concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004; 42: 4419-31.
23. Milovic NM, Wang J, Lewis K et al. Immobilized N-alkylated polyethylenimine avidly kills bacteria by rupturing cell membranes with no resistance developed. Biotechnol Bioeng 2005; 90: 715-22.
24. Ernsting MJ, Bonin GC, Yang M et al. Generation of cell adhesive substrates using peptide fluoralkyl surface modifiers. Biomaterials 2005; 26: 6536-46.
25. Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin: Isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci USA 1987; 84: 5449-53.
26. Lee JY, Boman A, Sun CX et al. Antibacterial peptides from pig intestine: Isolation of a mammalian cecropin. Proc Natl Acad Sci USA 1989; 86: 9159-62.